JPWO2017182802A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2017182802A5 JPWO2017182802A5 JP2018555644A JP2018555644A JPWO2017182802A5 JP WO2017182802 A5 JPWO2017182802 A5 JP WO2017182802A5 JP 2018555644 A JP2018555644 A JP 2018555644A JP 2018555644 A JP2018555644 A JP 2018555644A JP WO2017182802 A5 JPWO2017182802 A5 JP WO2017182802A5
- Authority
- JP
- Japan
- Prior art keywords
- vertigo
- subject
- treatment
- acetyl
- leucine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000012886 Vertigo Diseases 0.000 description 19
- 231100000889 vertigo Toxicity 0.000 description 18
- 208000002173 dizziness Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 description 10
- 229960000669 acetylleucine Drugs 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- WXNXCEHXYPACJF-UHFFFAOYSA-N N-acetyl-leucine Chemical compound CC(C)CC(C(O)=O)NC(C)=O WXNXCEHXYPACJF-UHFFFAOYSA-N 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000032683 aging Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000005021 gait Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 230000000926 neurological effect Effects 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000013433 lightheadedness Diseases 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 description 2
- 206010003591 Ataxia Diseases 0.000 description 2
- 206010008025 Cerebellar ataxia Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- 201000000200 vestibular neuronitis Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000027530 Meniere disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010047348 Vertigo positional Diseases 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 206010072731 White matter lesion Diseases 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001362 anti-vertigo Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000001870 benign paroxysmal positional vertigo Diseases 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- HXWLAJVUJSVENX-HFIFKADTSA-N ioflupane I(123) Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3CCCF)[C@H]2C(=O)OC)=CC=C([123I])C=C1 HXWLAJVUJSVENX-HFIFKADTSA-N 0.000 description 1
- 208000004343 lateral medullary syndrome Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000000337 motor cortex Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001144 postural effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007411 stabilization of membrane potential Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001103 thalamus Anatomy 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021185130A JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2024096260A JP2024123087A (ja) | 2016-04-19 | 2024-06-13 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1606834.8 | 2016-04-19 | ||
| GB201606834 | 2016-04-19 | ||
| PCT/GB2017/051090 WO2017182802A1 (en) | 2016-04-19 | 2017-04-19 | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021185130A Division JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2019513814A JP2019513814A (ja) | 2019-05-30 |
| JP2019513814A5 JP2019513814A5 (https=) | 2022-01-21 |
| JPWO2017182802A5 true JPWO2017182802A5 (https=) | 2022-01-21 |
| JP7387264B2 JP7387264B2 (ja) | 2023-11-28 |
Family
ID=58633040
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018555644A Active JP7387264B2 (ja) | 2016-04-19 | 2017-04-19 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2021185130A Active JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2024096260A Pending JP2024123087A (ja) | 2016-04-19 | 2024-06-13 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021185130A Active JP7506046B2 (ja) | 2016-04-19 | 2021-11-12 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
| JP2024096260A Pending JP2024123087A (ja) | 2016-04-19 | 2024-06-13 | 改善される運動性及び認知機能のためのアセチル－ロイシン又はその薬学的に許容される塩 |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US10905670B2 (https=) |
| EP (2) | EP4501406A3 (https=) |
| JP (3) | JP7387264B2 (https=) |
| KR (4) | KR102791288B1 (https=) |
| CN (2) | CN109069463B (https=) |
| AU (2) | AU2017252507B2 (https=) |
| BR (1) | BR112018071547A2 (https=) |
| CA (1) | CA3021155A1 (https=) |
| DK (1) | DK3445351T3 (https=) |
| ES (1) | ES2994242T3 (https=) |
| FI (1) | FI3445351T3 (https=) |
| HR (1) | HRP20241552T1 (https=) |
| HU (1) | HUE069219T2 (https=) |
| IL (3) | IL310508A (https=) |
| LT (1) | LT3445351T (https=) |
| MD (1) | MD3445351T2 (https=) |
| MX (2) | MX388461B (https=) |
| PL (1) | PL3445351T3 (https=) |
| PT (1) | PT3445351T (https=) |
| RS (1) | RS66142B1 (https=) |
| RU (1) | RU2745912C2 (https=) |
| SG (2) | SG10202106190RA (https=) |
| SI (1) | SI3445351T1 (https=) |
| SM (1) | SMT202400459T1 (https=) |
| WO (1) | WO2017182802A1 (https=) |
| ZA (1) | ZA201806849B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| WO2018029658A1 (en) | 2016-08-11 | 2018-02-15 | Intrabio Limited | Therapeutic agents for neurodegenerative diseases |
| GB201709459D0 (en) | 2017-06-14 | 2017-07-26 | Intrabio Ltd | Treatment for migraine |
| JP7471298B2 (ja) | 2018-12-06 | 2024-04-19 | イントラビオ エルティーディー | アセチル－ロイシンの重水素化類似体 |
| WO2020178721A1 (en) * | 2019-03-02 | 2020-09-10 | Intrabio Ltd. | Leucine, acetyl leucine, and related analogs for treating disease |
| US20250099355A1 (en) | 2023-07-18 | 2025-03-27 | Sytheon Ltd | Amino acid based salts, compositions and methods for treating skin and improving skin rejuvenation and longevity |
| WO2025166100A1 (en) | 2024-02-02 | 2025-08-07 | SynGAP Research Fund | Compositions and methods for treating neurodevelopmental disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060063827A1 (en) * | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| US20070190070A1 (en) * | 2004-09-03 | 2007-08-16 | Zeldis Jerome B | Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system |
| FR2883180B1 (fr) * | 2005-03-18 | 2007-05-25 | Pierre Fabre Medicament Sa | Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| US20080097606A1 (en) * | 2006-10-19 | 2008-04-24 | Cragg Andrew H | Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis |
| CA2687107A1 (en) * | 2007-05-08 | 2008-11-13 | Northern Innovations And Formulations Corp. | Branched-chain amino acid composition for improving skeletal muscle protein metabolism |
| US20120196257A1 (en) * | 2009-08-27 | 2012-08-02 | Joe Verghese | Cognitive function training to improve motor ability |
| TN2010000251A1 (fr) * | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| WO2012060844A1 (en) * | 2010-11-05 | 2012-05-10 | Biotie Therapies, Inc | A2a antagonists as cognition and motor function enhancers |
| TN2010000566A1 (en) * | 2010-12-03 | 2012-05-24 | Rekik Raouf | Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs |
| US10905670B2 (en) * | 2016-04-19 | 2021-02-02 | Intrabio Ltd. | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| US12458614B2 (en) * | 2017-10-18 | 2025-11-04 | Intrabio Ltd | Therapeutic agents for improved mobility and cognitive function and for treating neurodegenerative diseases and lysosomal storage disorders |
-
2017
- 2017-04-19 US US16/093,780 patent/US10905670B2/en active Active
- 2017-04-19 KR KR1020247003393A patent/KR102791288B1/ko active Active
- 2017-04-19 MX MX2018012739A patent/MX388461B/es unknown
- 2017-04-19 HR HRP20241552TT patent/HRP20241552T1/hr unknown
- 2017-04-19 CA CA3021155A patent/CA3021155A1/en active Pending
- 2017-04-19 FI FIEP17719692.0T patent/FI3445351T3/fi active
- 2017-04-19 KR KR1020227008412A patent/KR102413754B1/ko active Active
- 2017-04-19 IL IL310508A patent/IL310508A/en unknown
- 2017-04-19 KR KR1020187032983A patent/KR20180134398A/ko not_active Ceased
- 2017-04-19 PT PT177196920T patent/PT3445351T/pt unknown
- 2017-04-19 CN CN201780029480.6A patent/CN109069463B/zh active Active
- 2017-04-19 PL PL17719692.0T patent/PL3445351T3/pl unknown
- 2017-04-19 EP EP24205813.9A patent/EP4501406A3/en active Pending
- 2017-04-19 IL IL293266A patent/IL293266B2/en unknown
- 2017-04-19 CN CN202410876111.2A patent/CN118593463A/zh active Pending
- 2017-04-19 KR KR1020227021015A patent/KR102632670B1/ko active Active
- 2017-04-19 EP EP17719692.0A patent/EP3445351B1/en active Active
- 2017-04-19 HU HUE17719692A patent/HUE069219T2/hu unknown
- 2017-04-19 LT LTEPPCT/GB2017/051090T patent/LT3445351T/lt unknown
- 2017-04-19 AU AU2017252507A patent/AU2017252507B2/en active Active
- 2017-04-19 RU RU2018140131A patent/RU2745912C2/ru active
- 2017-04-19 SM SM20240459T patent/SMT202400459T1/it unknown
- 2017-04-19 SG SG10202106190RA patent/SG10202106190RA/en unknown
- 2017-04-19 BR BR112018071547-6A patent/BR112018071547A2/pt not_active Application Discontinuation
- 2017-04-19 JP JP2018555644A patent/JP7387264B2/ja active Active
- 2017-04-19 SI SI201731566T patent/SI3445351T1/sl unknown
- 2017-04-19 IL IL262379A patent/IL262379B/en unknown
- 2017-04-19 ES ES17719692T patent/ES2994242T3/es active Active
- 2017-04-19 MD MDE20190248T patent/MD3445351T2/ro unknown
- 2017-04-19 RS RS20241222A patent/RS66142B1/sr unknown
- 2017-04-19 WO PCT/GB2017/051090 patent/WO2017182802A1/en not_active Ceased
- 2017-04-19 SG SG11201809031XA patent/SG11201809031XA/en unknown
- 2017-04-19 DK DK17719692.0T patent/DK3445351T3/da active
-
2018
- 2018-10-15 ZA ZA2018/06849A patent/ZA201806849B/en unknown
- 2018-10-18 MX MX2021014844A patent/MX2021014844A/es unknown
-
2020
- 2020-12-22 US US17/247,757 patent/US11998518B2/en active Active
-
2021
- 2021-11-12 JP JP2021185130A patent/JP7506046B2/ja active Active
-
2022
- 2022-10-17 AU AU2022256077A patent/AU2022256077A1/en not_active Abandoned
-
2023
- 2023-07-10 US US18/349,221 patent/US12329733B2/en active Active
-
2024
- 2024-06-13 JP JP2024096260A patent/JP2024123087A/ja active Pending
-
2025
- 2025-05-13 US US19/206,473 patent/US20250332133A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7650929B2 (ja) | 成人における焦点てんかんの処置のための合成経皮的カンナビジオール | |
| RU2499598C2 (ru) | Способы лечения нарушений с применением селективного антагониста nr2b-подтипа nmda рецепторов | |
| JP2021502403A (ja) | 遺伝性てんかん性障害の処置に使用するガナキソロン | |
| JP6466540B2 (ja) | 多発性硬化症を治療するためのＰＰＡＲγアゴニスト | |
| JP6789579B2 (ja) | 特定の患者集団において神経変性障害を処置する方法 | |
| US11083735B2 (en) | Methods for treating sleep disorders, sleep disturbances, and related symptoms using aminosterol compositions | |
| JP2002527474A (ja) | 躁病および双極性障害の治療法 | |
| JP7319421B2 (ja) | アルツハイマー病を治療するための抗ａベータプロトフィブリル抗体及びベータ－セクレターゼｂａｃｅ１阻害剤を含む組成物 | |
| US12084491B2 (en) | Treatment of Parkinson's disease | |
| JP2012197304A (ja) | ミオパシー関連性の覚醒障害を矯正することが意図される医薬品を製造するためのモダフィニルの使用 | |
| CN107835695A (zh) | 用于治疗自闭症的组合物和方法 | |
| KR20180034442A (ko) | 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료 | |
| CN101257898A (zh) | 艾司佐匹克隆与o-去甲基文拉法辛的组合以及治疗绝经期和心境障碍、焦虑症和认知障碍的方法 | |
| EP4395753A1 (en) | Fenfluramine for treatment of demyelinating diseases and conditions | |
| JPWO2017182802A5 (https=) | ||
| RS67601B1 (sr) | Terapijski agensi za upotrebu u lečenju sindroma nemirnih nogu | |
| JPH0344324A (ja) | 性機能賦活剤 | |
| KR102693607B1 (ko) | 하지 불안 증후군을 치료하기 위한 치료제 | |
| EP4590304A1 (en) | Methods of reducing neurodegeneration associated with neurodegenerative diseases | |
| US20230372364A1 (en) | Method of treating gaba mediated disorders | |
| JP2002513759A (ja) | 神経発達障害の処置における４−ピペリジンメタノール誘導体の使用 | |
| WO2020196694A1 (ja) | 嗅覚障害及び神経変性疾患の治療及び／又は予防剤 | |
| CN103599114A (zh) | 一种含冰片的1，6-二磷酸果糖钠盐的药物用途 | |
| US20200038417A1 (en) | Methods and compositions for treating cognitive impairment | |
| RU2802288C2 (ru) | Терапевтические агенты для лечения синдрома беспокойных ног |